<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240626</url>
  </required_header>
  <id_info>
    <org_study_id>1452523</org_study_id>
    <nct_id>NCT04240626</nct_id>
  </id_info>
  <brief_title>Multimodal Analgesia Effect on Post Surgical Patient</brief_title>
  <official_title>Multimodal Analgesia Effect on Post Surgical Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing Bariatric Surgery at the University of California Davis Medical Center
      will be divided into two groups, one receiving Standard of Care pain control medications vs
      the second group which will receive non-narcotic pain medications with rescue pain
      medications available if needed
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain control after weight loss surgery is challenging due to the alteration of digestive
      system anatomy and limitation on using medications which can either be crushed or in liquid
      form for the first 10 days to 14 days after surgery. Additionally there are multiple programs
      in place to eliminate the use of narcotic/opioid based pain medications due their potential
      addictive risks.

      This study compares two groups of patients whom will have Roux en Y Gastric Bypass Surgery at
      UC Davis Medical Center, the control group will receive standard of care pain control
      medications (including opioid based medications) compared to the research arm, this group
      will receive Gabapentinin and Tylenol for pain control after surgery with rescue pain
      medications available if needed.

      Post surgery both groups will be managed by the Bariatric Surgery Team and will be contacted
      periodically as part of the standard of care to monitor pain control and usage of any rescue
      medications (if needed).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will receive Gabapentin and Ofirmev post surgery (dosage based on patients pre-operative weight) with on-call medications as needed including narcotic analgesia for breakthrough pain control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patients agreeing to participate in the study will be assigned one of two treatment arms. Neither the care team nor the patient will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change In Post Operative Pain Intensity</measure>
    <time_frame>3 Days and 14 Days Post Surgery</time_frame>
    <description>Using the Wong-Baker Pain Rating Scale-0=No Pain, 2-4, Slight Pain, 6-8, Moderate Pain, 9-10, Severe Pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oral Morphine Equivalence (OME) from 3 days and 14 days post surgery</measure>
    <time_frame>3 Days and 14 Days Post Surgery</time_frame>
    <description>OME Table is used to measure opioid use post surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Surgery</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group will receive the standard of care pain control protocol after index Bariatric Surgery which includes the use of a PCA (patient controlled analgesia) with Dilaudid or Morphine Sulphate, transitioning to oral narcotic based pain control medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neurontin</intervention_name>
    <description>600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <other_name>Gabapentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilaudid Injectable Product</intervention_name>
    <description>.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Hydromorphone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine Injectable Product</intervention_name>
    <description>0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Hydrochloride</intervention_name>
    <description>1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hycet 7.5Mg-325Mg/15Ml Solution</intervention_name>
    <description>Dosage: 10-15ml q4h prn for pain control</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Hydrocodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran Injection</intervention_name>
    <description>4 mg IV for nausea control while inpatient, prn</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Odanesetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine patch</intervention_name>
    <description>Topical application patch for nausea control, used with/without Ativan.</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Scopolamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ativan</intervention_name>
    <description>0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flexeril Oral Product</intervention_name>
    <description>5 mg orally q8h prn for muscle spasms.</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Cyclobenziparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol Suspension</intervention_name>
    <description>1000 mg q6h PRN for pain control.</description>
    <arm_group_label>Multi-Modal</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who undergo index weight loss procedures at UC Davis Medical Center

          -  Women with a BMI =&gt;30

          -  Age from 35-65

          -  American Society of Anesthesiology (ASA) score of 3 or less

          -  No previous history of prior abdominal/foregut surgery

        Exclusion Criteria:

          -  Not having an index weight los surgery for obesity

          -  Do not meet the NIH Standards for weight loss surgery

          -  Additional planned or unplanned procedures during the index surgical procedure such as
             Cholecystectomy or extensive lysis of adhesions (&gt;30 minutes)

          -  BMI &lt; 30

          -  Men

          -  Women considering or currently planning on gender altering/modification

          -  ASA score of 4 or higher

          -  Patients less than 35 years of age or older than 65 years of age at the time of
             surgical consent

          -  A history of open abdominal surgery including umbilical, ventral, or splengalic hernia
             repair with or without mesh implantation, transplant or vascular surgery or any
             foregut procedures including hiatal hernia repair or anti-reflux surgery

          -  Arthritis, Fibromyalgia, chronic pain syndrome

          -  Other conditions requiring daily use of oral pain medications

          -  Prisoners

          -  Allergy to Gabapentin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed R Ali, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Jachniewicz, MSN, CRNFA,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nurse Practitioner, Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Smith, BS, CCRP</last_name>
    <phone>916-734-7820</phone>
    <email>whsmith@ucdavis.edu</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric Surgery,</keyword>
  <keyword>Pain Control</keyword>
  <keyword>Gabapentinin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

